MLTX | MoonLake Immunotherapeutics Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	40.24 - 42.53
52 Week Range	31.42 - 58.26
Beta	1.08
Implied Volatility	81.70%
IV Rank	30.35%
Day's Volume	456,916
Average Volume	420,400
Shares Outstanding	63,474,300
Market Cap	2,670,998,544
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-20

Valuation
Profitability
Growth
Health
P/E Ratio	-22.26
Forward P/E Ratio	N/A
EPS	-1.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	50
Country	Switzerland
Website	MLTX

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MLTX's peers: CMPX, GLTO, GNLX, IDYA, ITOS, MIRM, VRNA, TERN, DAWN, ABOS, AMLX, AVTE, ELVN, GPCR, VTYX, NUVL, CERE, TVTX, ACLX, AKRO, ETNB, PLRX, IRON

*Chart delayed

Analyzing fundamentals for MLTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MLTX Fundamentals page.

Watching at MLTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on MLTX Technicals page.